Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). In a filing disclosed on December 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in BioCryst Pharmaceuticals stock on November 13th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of First Watch Restaurant Group (NASDAQ:FWRG) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of TKO Group (NYSE:TKO) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 11/24/2025.
• Purchased $1,001 – $15,000 in shares of Logan Energy (CVE:LGN) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Primoris Services (NASDAQ:PRIM) on 11/24/2025.
• Purchased $15,001 – $50,000 in shares of LandBridge (NYSE:LB) on 11/21/2025.
• Purchased $50,001 – $100,000 in shares of LandBridge (NYSE:LB) on 11/20/2025.

BioCryst Pharmaceuticals Stock Up 1.6%

BCRX stock opened at $7.41 on Friday. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $11.31. The firm has a market cap of $1.56 billion, a P/E ratio of -148.20, a P/E/G ratio of 0.70 and a beta of 0.91. The company’s 50-day moving average price is $7.17 and its two-hundred day moving average price is $8.14.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The firm had revenue of $159.40 million for the quarter, compared to the consensus estimate of $162.91 million. BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The business’s revenue was up 36.1% on a year-over-year basis. During the same period last year, the company posted ($0.07) EPS. Equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Needham & Company LLC cut their target price on BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. JMP Securities upped their price objective on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a research report on Wednesday, October 15th. Zacks Research lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. HC Wainwright lifted their target price on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, TD Cowen initiated coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 15th. They issued a “buy” rating and a $30.00 target price for the company. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Family Legacy Financial Solutions LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at about $72,000. Focus Partners Wealth bought a new position in BioCryst Pharmaceuticals in the 3rd quarter valued at approximately $77,000. Farther Finance Advisors LLC boosted its position in BioCryst Pharmaceuticals by 326.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock worth $80,000 after buying an additional 8,109 shares during the period. Vestmark Advisory Solutions Inc. bought a new stake in BioCryst Pharmaceuticals during the 3rd quarter worth approximately $81,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in BioCryst Pharmaceuticals in the 3rd quarter valued at approximately $81,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Insider Activity

In other news, insider Alane P. Barnes sold 91,004 shares of BioCryst Pharmaceuticals stock in a transaction on Monday, December 1st. The shares were sold at an average price of $7.10, for a total transaction of $646,128.40. Following the transaction, the insider owned 416,152 shares in the company, valued at approximately $2,954,679.20. The trade was a 17.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 161,680 shares of company stock worth $1,164,401 over the last ninety days. 5.10% of the stock is currently owned by company insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.